Proagio is under clinical development by ProDa BioTech and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Proagio’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Proagio Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Proagio overview

Proagio is under development for the treatment of solid tumors including pancreatic cancer, prostate cancer, treatment-resistant cancers, including triple-negative breast cancer and liver cancer. It acts by targeting integrin alpha V beta 3.

Quick View Proagio LOA Data

Report Segments
  • Innovator
Drug Name
  • Proagio
Administration Pathway
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: ProDa BioTech
  • Originator: Georgia State University
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.